October 25, 2022 — RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ASTRO 2022, to be held in San Antonio, October 23-25. Attendees can book demonstrations of RayStation* treatment planning system, RayCare* oncology information system, and RayIntelligence, the cloud-based oncology analytics system, in RaySearch’s booth 3785 during the congress. 

October 25, 2022 — A new study offers a new option to patients with oligometastatic prostate cancer who want relief from hormone therapy without compromising the risk of their disease spreading.

October 24, 2022 — CIVCO Radiotherapy, the leading global provider of high quality, innovative, patient-centric radiotherapy solutions, will feature the TotalRT All in One Solution along with several innovative solutions in booth #3766 at the ASTRO Annual Meeting in San Antonio, Texas, October 23-25, 2022. 

October 24, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a new modality for treating all stages of cancer, today announced eight clinical abstracts evaluating the potential use and utility of its novel technology were accepted for presentation during the Americ

October 24, 2022 — Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, today introduced its new product, the MEVION S250-FIT Proton Therapy System. 

October 24, 2022 — A three-week course of radiation therapy is as safe and effective as four to six weeks of treatment for patients with early-stage breast cancer who have a higher risk of having their tumors recur, results of a randomized phase III clinical trial show.

October 24, 2022 — An artificial intelligence (AI) model developed by researchers can predict the likelihood that a patient may have an unplanned hospitalization during their radiation treatments for cancer.

October 24, 2022 — Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients’ quality of life, a randomized phase III clinical trial shows.

October 24, 2022 — In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.

October 23, 2022 — Treating high-risk, asymptomatic bone metastases with radiation may reduce painful complications and hospitalizations and possibly extend overall survival in people whose cancer has spread to multiple sites, a phase II clinical trial suggests.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now